1 EXHIBIT 10.6 CLINICAL DEVELOPMENT AGREEMENT PROTOCOL #VIT-02-08961X AND PROTOCOL #VIT-03-08961X: Two Phase III Safety and Efficacy Studies of Vitrase(TM) (Hyaluronidase for Ophthalmic Intravitreal Injection) for Clearance of Severe Vitreous...Clinical Development Agreement • April 5th, 2000 • Ista Pharmaceuticals Inc • New Jersey
Protalix, Pfizer enter clinical development dealClinical Development Agreement • October 24th, 2021
MASTERClinical Development Agreement • December 21st, 2001 • Corcept Therapeutics Inc • California
AGREEMENT BETWEEN DARA THERAPEUTICS, INC., A SUBSIDIARY OF DARA BIOSCIENCES, INC., AND THE DIVISION OF CANCER PREVENTION, NATIONAL CANCER INSTITUTE FOR THE CLINICAL DEVELOPMENT OF KRN5500 INTRODUCTIONClinical Development Agreement • April 30th, 2010 • DARA BioSciences, Inc. • Pharmaceutical preparations • District of Columbia
The Division of Cancer Prevention (DCP), National Cancer Institute (NCI), recognizes the importance of the pharmaceutical industry in the clinical development of new cancer prevention and control agents. DCP wishes to foster collaboration with industry wherever possible. As part of its mission to improve cancer care, DCP shares with industry the important goal of defining the contribution of a new drug or biologic in the treatment, prevention and control of cancer. DCP therefore recognizes and supports the need of a private sponsor to focus at the appropriate time on clinical trials which lead to a New Drug Application (NDA) and a Biological License Application (BLA), since an NDA and a BLA are the vehicles through which new cancer prevention and control therapies become widely available to cancer patients and the public. Thus DCP considers it appropriate for the investigators sponsored by DCP to do clinical trials of interest to, and partially supported by, a pharmaceutical firm, prov
